Back to Search Start Over

Willingness to randomize primary medium vessel occlusions for endovascular treatment

Authors :
Johanna M. Ospel
Nishita Singh
Noboyuki Sakai
Petra Cimflova
Nima Kashani
Bijoy K Menon
Manon Kappelhof
Rosalie McDonough
Mayank Goyal
Michael Chen
Jens Fiehler
Graduate School
Radiology and Nuclear Medicine
ACS - Atherosclerosis & ischemic syndromes
ACS - Microcirculation
ANS - Cellular & Molecular Mechanisms
ANS - Compulsivity, Impulsivity & Attention
ANS - Neurovascular Disorders
Source :
Journal of neuroradiology. Journal de neuroradiologie. Elsevier Masson
Publication Year :
2021

Abstract

Background and purpose Patients with acute ischemic stroke due to medium vessel occlusion (MeVO) make up a substantial part of the acute stroke population, though guidelines currently do not recommend endovascular treatment (EVT) for them. A growing body of evidence suggests that EVT is effective in MeVOs, including observational data but no randomized studies. We aimed to explore willingness of physicians worldwide to randomize MeVO stroke patients into a hypothetical trial comparing EVT in addition to best medical management versus best medical management only. Methods In an international cross-sectional survey among stroke physicians, participants were presented with 4 cases of primary MeVOs (6 scenarios each). Each subsequent scenario changed one key patient characteristic compared to the previous one, and asked survey participants whether they would be willing to randomize the described patient. Overall, physician- and scenario-specific decision rates were calculated. Multivariable logistic regression with clustering by respondent was performed to assess factors influencing the decision to randomize. Results Overall, 366 participants (56 women) from 44 countries provided 8784 answers to 24 MeVO case scenarios. The majority of responses (78.3%) were in favor of randomizing. Most physicians were willing to accept patients transferred for EVT from a primary center (82%) and the majority of these (76.5%) were willing to randomize these patients after transfer. Patient age > 65 years, A3 occlusion, small core volume, and patient intravenous alteplase eligibility significantly influenced the physician's decision to randomize (adjOR 1.24, 95%CI 1.13–1.36; adjOR 1.17, 95%CI 1.01–1.34; adjOR 0.98, 95%CI 0.97–0.99 and adjOR 1.38, 95%CI 1.21–1.57, respectively). Conclusions Most physicians in this survey were willing to randomize acute MeVO stroke patients irrespective of patient characteristics into a trial comparing EVT in addition to best medical management versus best medical management only, suggesting there is clinical equipoise.

Details

Language :
English
ISSN :
01509861
Database :
OpenAIRE
Journal :
Journal of neuroradiology. Journal de neuroradiologie
Accession number :
edsair.doi.dedup.....9a7411a7592145bd4a92af806ba7c758
Full Text :
https://doi.org/10.1016/j.neurad.2021.08.001